New approach to testing for infections of the genital tract

- BACTERIAL VAGINOSIS
- CANDIDA
- CHLAMYDIA
- GONORRHEA
- TRICHOMONAS
- HSV 1/2
- MYCO/UREAPLASMAS
Symptoms resulting from genital tract infections are among the most common reasons patients visit obstetricians and gynecologists.\(^1\)

**NuSwab\textsuperscript{®} Bacterial Vaginosis**

Result interpretation provides actionable information.

For bacterial vaginosis (BV), merely identifying the presence or absence of bacteria may not differentiate normal levels of bacteria from abnormal levels.\(^1\) Numerous organisms associated with BV are also considered normal vaginal flora. LabCorp’s new BV assay identifies bacterial imbalance quantitatively using only three marker organisms.

**Quantitative markers backed by clinical study**

In a clinical study, LabCorp found excellent correlation of three BV markers (*Atopobium vaginae*, Bacterial vaginosis-associated bacterium [BVAB]-2, *Megasphaera*-1) to Nugent Gram stain score and Amsel clinical diagnosis. LabCorp found that additional BV markers studied did not improve overall test performance.

**Organisms analyzed for concentrations and scored**

Each organism’s score translated into a total score.

<table>
<thead>
<tr>
<th>Example</th>
<th>Atopobium vaginae</th>
<th>BVAB-2</th>
<th>Megasphaera-1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Score Interpretation: Positive</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Result interpretation**

Provider-friendly interpretation based on total score.

<table>
<thead>
<tr>
<th>Total Score</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>3-6</td>
<td>Positive - indicative of bacterial vaginosis.</td>
</tr>
<tr>
<td>0-1</td>
<td>Negative - not indicative of bacterial vaginosis.</td>
</tr>
<tr>
<td>2</td>
<td>Indeterminate - unable to determine BV status. Additional clinical and laboratory data should be evaluated to establish a diagnosis.</td>
</tr>
</tbody>
</table>

**NuSwab\textsuperscript{®} VG and VG+**

Targeted profiles, fewer tests

Determining the underlying cause of vaginitis can be difficult.

- NuSwab VG combines tests for BV, *C. albicans*, *C. glabrata*, and *Trichomonas*, common causes of vaginitis.\(^1\)
- NuSwab VG+ adds *Chlamydia* and *Gonorrhea* tests to NuSwab VG to aid in the identification of STD coinfection.
NuSwab® *C albicans* and *C glabrata*
Cost-effective testing with actionable results.

Two species of *Candida* comprise approximately 93% to 97%\textsuperscript{2,3} of *Candida* species in vulvovaginal candidasis according to two large US studies. LabCorp's new *C albicans* and *C glabrata* test differentiates the two most prevalent species of *Candida*. In addition, *C albicans* and *C glabrata* have different –azole resistance characteristics. This differentiation may help guide appropriate therapy selection.

**Target the most prevalent organisms**
In two large US clinical studies, *C albicans* and *C glabrata* accounted for approximately 93% to 97%\textsuperscript{2,3} of *Candida* species found. Additional *Candida* species testing is available upon request.

**Candida Species Prevalence in VVC**

<table>
<thead>
<tr>
<th>Species</th>
<th>Prevalence (n=93,775)\textsuperscript{2}</th>
<th>Prevalence (n=429)\textsuperscript{3}</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>C albicans</em></td>
<td>89.0%</td>
<td>77.3%</td>
</tr>
<tr>
<td><em>C glabrata</em></td>
<td>7.9%</td>
<td>15.9%</td>
</tr>
<tr>
<td><strong>Subtotal</strong></td>
<td>96.9%</td>
<td>93.2%</td>
</tr>
<tr>
<td><em>C parapsilosis</em></td>
<td>1.7%</td>
<td>3.9%</td>
</tr>
<tr>
<td><em>C krusei</em></td>
<td>--</td>
<td>1.6%</td>
</tr>
<tr>
<td><em>C tropicalis</em></td>
<td>1.4%</td>
<td>1.1%</td>
</tr>
<tr>
<td><em>C lusitaniae</em></td>
<td>--</td>
<td>0.2%</td>
</tr>
</tbody>
</table>

**Differentiate species for treatment**
*C albicans* and *C glabrata* have different antifungal resistance profiles. *C glabrata* and *C krusei* have been shown to be more resistant to fluconazole. In a large study of –azole susceptibility, approximately 67% of *C glabrata* isolates demonstrated decreased susceptibility.\textsuperscript{3,4}

**Candida Species with Decreased Susceptibility to Fluconazole**

<table>
<thead>
<tr>
<th>Candida Species</th>
<th>% Resistant</th>
<th>% Susceptible-Dose Dependent</th>
<th>Total % Decreased Susceptibility</th>
<th>Antifungals without Decreased Susceptibility</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>C glabrata</em></td>
<td>15.2%</td>
<td>51.8%</td>
<td>67.0%</td>
<td>Fluconazole, Imidazoles, Nystatin</td>
</tr>
<tr>
<td><em>C krusei</em></td>
<td>Intrinsically resistant</td>
<td>Intrinsically resistant</td>
<td>Intrinsically resistant</td>
<td>Imidazoles, Nystatin</td>
</tr>
</tbody>
</table>

In the same study, *C albicans*, *C parapsilosis*, *C tropicalis*, *C lusitaniae* did not exhibit any significant decreased fluconazole susceptibility.

**NuSwab® STD**
Convenient, high-quality STD testing

NuSwab STD portfolio gives you the option to test for as many as four common sexually transmitted infections with one vaginal swab collection.

- *Chlamydia* and *Gonorrhea*
- *Trichomonas*
- Herpes (HSV) types 1 and 2
**NuSwab® Portfolio**

The NuSwab portfolio combines high-quality testing with the convenience of a single-swab collection, providing reliable and actionable information to manage your patients better. The NuSwab test menu offers a targeted approach for clinically appropriate, cost-effective care with profiles that contain fewer, select individual tests without sacrificing the content needed for comprehensive results. Better information from fewer tests . . . smart testing has arrived.

For the most current information regarding test options, including CPT codes, please consult the Test Menu at www.labcorp.com.

LabCorp's policy is to provide physicians, in each instance, with the flexibility to choose appropriate tests to assure that the convenience of ordering test combinations/profiles does not prevent physicians who wish to order a test combination/profile from making deliberate informed decisions regarding which tests are medically necessary. All the tests offered in test combinations/profiles may be ordered individually using the LabCorp test request form.

Behind Every Test at LabCorp is a Dedicated, Experienced Team of Scientists

The senior scientific directors behind LabCorp's NuSwab portfolio have extensive experience in women's health and oversee laboratories that perform hundreds of thousands of tests annually. These senior directors collectively have more than 100 years of postdoctoral experience in microbiology, immunology, virology, and molecular biology. They have served as active faculty or guest presenters at numerous colleges and universities and authored or coauthored more than 200 publications and abstracts spanning four decades.

For the most current information regarding test options, including CPT codes, please consult the Test Menu at www.labcorp.com.

LabCorp's policy is to provide physicians, in each instance, with the flexibility to choose appropriate tests to assure that the convenience of ordering test combinations/profiles does not prevent physicians who wish to order a test combination/profile from making deliberate informed decisions regarding which tests are medically necessary. All the tests offered in test combinations/profiles may be ordered individually using the LabCorp test request form.

**References**